Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238739 | 0.81 | MAPK14 (0.36) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL3235753 | 0.63 | MAPK14 (0.35) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL5443561 | 0.63 | CSNK1D (0.70) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL22068158 | 0.63 | IDO1 (0.55) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL2848951 | 0.63 | MAPK14 (0.37) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL3228998 | 0.62 | CSNK1D (0.40) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6091007 | 0.60 | PTGS2 (0.56) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL2847071 | 0.60 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL8836231 | 0.59 | TDO2 (0.45) | MAPK14MAPK13MAPK12MAPK11GRM5 | |
| SCHEMBL31395006 | 0.58 | IDO1 (0.35) | MAPK14MAPK13MAPK12MAPK11SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | Merckle (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-2054404-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008023066-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MIF, TNF, IL1B | MAPK14 2368/4885MAPK13 2173/4885MAPK12 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.